Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia
Status:
Completed
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
The primary objective is to estimate the overall event-free survival of children at least one
year of age at diagnosis who are treated with risk-directed therapy and to monitor the
molecular remission induction rate.